Tags

Type your tag names separated by a space and hit enter

Targeted 307 nm UVB-phototherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol.
Skin Res Technol. 2012 May; 18(2):212-8.SR

Abstract

BACKGROUND

Phototherapy is a cornerstone in treatment of moderate-to-severe psoriasis. Narrow-band UVB has been shown to be a potent therapeutic tool. To reduce the potential carcinogenic risk, targeted phototherapy has been developed using excimer lasers or excimer light devices (ELD).

OBJECTIVE

The role of excimer light therapy in practice and modes of action are not completely understood. We wanted to investigate a 307 nm ELD for plaque psoriasis in comparison with topical dithranol therapy twice daily.

METHODS

We conducted a pilot trial in 21 adult patients with moderate plaque-type psoriasis. Two target lesions of comparable size and plaque-modified Psoriasis Activity and Severity Index (PSI) scores were selected. Lesion A was treated three times using a newly developed 307 nm ELD. Lesion B was treated twice daily with dithranol ointment. The mean period of treatment was 9 days. Clinical evaluation included PSI scores, safety, time needed to treat, and patient's satisfaction. In addition, fluorescence-remission imaging technique was used for objective evaluation.

RESULTS

Both treatments improved the PSI score (mean 3.0 points). The treatments were safe but ELD was more convenient for patients. The time needed to treat the target lesion was significantly shorter with ELD. Targeted UVB therapy normalized NADH fluorescence in lesional skin.

CONCLUSIONS

The 307 nm excimer light therapy for plaque type psoriasis was equipotent to twice daily topical dithranol. Efficacy, safety, and convenience suggest that targeted UVB therapy with quasi monochromatic light is a new useful treatment option for patients with limited psoriatic plaques.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Wollina U
Department of Dermatology and Allergology, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of Technical University of Dresden, Dresden, Germany. wollina-uw@khdf.de
Koch A
No affiliation info available
Scheibe A
No affiliation info available
Seme B
No affiliation info available
Streit I
No affiliation info available
Schmidt WD
No affiliation info available

MeSH

Administration, TopicalAdultAgedAged, 80 and overAnthralinDermatologic AgentsFemaleHumansLasers, ExcimerLow-Level Light TherapyMaleMiddle AgedPilot ProjectsPsoriasisSeverity of Illness IndexUltraviolet Therapy

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

22092772

Citation

Wollina, Uwe, et al. "Targeted 307 Nm UVB-phototherapy in Psoriasis. a Pilot Study Comparing a 307 Nm Excimer Light With Topical Dithranol." Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), vol. 18, no. 2, 2012, pp. 212-8.
Wollina U, Koch A, Scheibe A, et al. Targeted 307 nm UVB-phototherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol. Skin Res Technol. 2012;18(2):212-8.
Wollina, U., Koch, A., Scheibe, A., Seme, B., Streit, I., & Schmidt, W. D. (2012). Targeted 307 nm UVB-phototherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol. Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 18(2), 212-8. https://doi.org/10.1111/j.1600-0846.2011.00556.x
Wollina U, et al. Targeted 307 Nm UVB-phototherapy in Psoriasis. a Pilot Study Comparing a 307 Nm Excimer Light With Topical Dithranol. Skin Res Technol. 2012;18(2):212-8. PubMed PMID: 22092772.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeted 307 nm UVB-phototherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol. AU - Wollina,Uwe, AU - Koch,André, AU - Scheibe,Armin, AU - Seme,Bernd, AU - Streit,Ingolf, AU - Schmidt,Wolf-Dieter, Y1 - 2011/09/04/ PY - 2011/07/07/accepted PY - 2011/11/19/entrez PY - 2011/11/19/pubmed PY - 2012/8/8/medline SP - 212 EP - 8 JF - Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) JO - Skin Res Technol VL - 18 IS - 2 N2 - BACKGROUND: Phototherapy is a cornerstone in treatment of moderate-to-severe psoriasis. Narrow-band UVB has been shown to be a potent therapeutic tool. To reduce the potential carcinogenic risk, targeted phototherapy has been developed using excimer lasers or excimer light devices (ELD). OBJECTIVE: The role of excimer light therapy in practice and modes of action are not completely understood. We wanted to investigate a 307 nm ELD for plaque psoriasis in comparison with topical dithranol therapy twice daily. METHODS: We conducted a pilot trial in 21 adult patients with moderate plaque-type psoriasis. Two target lesions of comparable size and plaque-modified Psoriasis Activity and Severity Index (PSI) scores were selected. Lesion A was treated three times using a newly developed 307 nm ELD. Lesion B was treated twice daily with dithranol ointment. The mean period of treatment was 9 days. Clinical evaluation included PSI scores, safety, time needed to treat, and patient's satisfaction. In addition, fluorescence-remission imaging technique was used for objective evaluation. RESULTS: Both treatments improved the PSI score (mean 3.0 points). The treatments were safe but ELD was more convenient for patients. The time needed to treat the target lesion was significantly shorter with ELD. Targeted UVB therapy normalized NADH fluorescence in lesional skin. CONCLUSIONS: The 307 nm excimer light therapy for plaque type psoriasis was equipotent to twice daily topical dithranol. Efficacy, safety, and convenience suggest that targeted UVB therapy with quasi monochromatic light is a new useful treatment option for patients with limited psoriatic plaques. SN - 1600-0846 UR - https://www.unboundmedicine.com/medline/citation/22092772/Targeted_307_nm_UVB_phototherapy_in_psoriasis__A_pilot_study_comparing_a_307_nm_excimer_light_with_topical_dithranol_ L2 - https://doi.org/10.1111/j.1600-0846.2011.00556.x DB - PRIME DP - Unbound Medicine ER -